Biopharming is the process of producing (or 'farming') medicinal compounds for therapeutic use using transgenic plants or animals. This entails putting target genes into hosts (crops or animals) that would not usually express them. The desired component may be expressed in a form that may be harvested on a regular basis (e.g., milk, eggs, fruits, etc.). The use of crops for bio-production of a recombinant protein (i.e., enzyme or antibody) or a system that includes bioreactors in vitro is referred to as biopharming. In comparison to industrial expenses, this approach provides great economic and health benefits, aided by new biotechnology methods that are improving. Plant biopharming is described as the cultivation of transgenic plants that have been genetically modified to produce "humanised" medicinal compounds for human use. "Molecular farming" is another term for biopharming. Corn, soybeans, rice, tobacco, and potatoes engineered to generate a material, usually a protein, vaccines, in their fruit, leaves, seeds, or tubers, are the most popular plants now being investigated for biopharming.
Title : Renewed novel biotech ideas, with bioreactor bioengineering economic impact
Murray Moo Young, University of Waterloo, Canada
Title : Osmotic lysis–driven Extracellular Vesicle (EV) engineering
Limongi Tania, University of Turin, Italy
Title : Steps and strides: Cross-species insights into movement and injury
Babak Faramarzi, Western University of Health Sciences, United States
Title : Eliminating implant failure in humans with nano chemistry: 45,000 cases and counting
Thomas J Webster, Brown University, United States
Title : Scientist’s computational lawyer
Julia Sidorova, Instituto Carlos III de Salud (CIBER-EHD), Spain
Title : Evaluating cell compatibility and subcutaneous host response of silk fibroin–chitosan plug composites as potential resorbable implants
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico